A real‐life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis

Abstract

Psoriasis is a skin disorder characterized by chronic inflammation driven by different immunologic pathways, among which the IL‐23/Th17 axis plays a pivotal role. For this reason, the use of IL23p19 inhibitors in psoriasis treatment has been evaluated over the years. Guselkumab, a totally human IgG1 lambda monoclonal antibody, that selectively blocks the p 19 subunit of IL‐ 23 has demonstrated high efficacy and safety throughout several, randomized, double‐blind phase III trials (VOYAGE 1 and 2, NAVIGATE and ECLIPSE). We designed a single‐center retrospective cohort study in a population consisting of 46 patients followed from December 2018 to April 2021. After a diagnosis of moderate to severe psoriasis, all the patients were considered suitable to receive treatment with Guselkumab. In our population, among those who achieved clinical improvement in terms of Psoriasis Area Severity Index (PASI), PASI 75, 90, and 100 were achieved on average on weeks 14, 19, 21 respectively. We then analyzed a subgroup of our population, consisting of 35 patients, who had an identical follow‐up time of 28 weeks, thus observing the trend in mean PASI at subsequent assessments and the number of patients who had reached PASI 75, PASI 90, and PASI 100 at week 4 (10; 3; 1), week 12 (12; 13; 11), week 20 (7; 6; 2), and week 28 (1; 4; 6), respectively. The results obtained are in line with those obtained from previous studies, thus confirming that Guselkumab is an excellent choice in terms of security, long‐term efficacy, and overall tolerance.

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

“…A single-center retrospective cohort study in a population consisting of 46 patients, followed from December 2018 to April 2021, PASI 75, 90, and 100 were achieved on average on weeks 14, 19, and 21 respectively. 29 In a subgroup of this population, consisting of 35 patients, PASI 75, PASI 90, and PASI 100 were reached at week 28 by 85.7%, 74.3%, and 57.1%, respectively. 29 No patients dropped out of the study due to AE nor to inefficacy of the biologic agent.…”

“… 29 In a subgroup of this population, consisting of 35 patients, PASI 75, PASI 90, and PASI 100 were reached at week 28 by 85.7%, 74.3%, and 57.1%, respectively. 29 No patients dropped out of the study due to AE nor to inefficacy of the biologic agent. 29 A multicentric study retrospectively evaluated 135 patients with psoriasis treated with guselkumab from June 2018 until November 2020, assessing efficacy using the degree of improvement in the PASI scores at baseline and after 4, 12, 20, 28, and 36 weeks.…”

“… 29 No patients dropped out of the study due to AE nor to inefficacy of the biologic agent. 29 A multicentric study retrospectively evaluated 135 patients with psoriasis treated with guselkumab from June 2018 until November 2020, assessing efficacy using the degree of improvement in the PASI scores at baseline and after 4, 12, 20, 28, and 36 weeks. 30 At week 36, the proportion of patients achieving PASI 75 and PASI 90 was 67% and 37%, respectively.…”

The feasibility of the use of monoclonal antibodies to interleukin 23 in the therapy of severe psoriasis with the eluding effect of genetically engineered biological drugs

“…Псориаз -это заболевание кожи, ассоциирующееся с повышенным риском возникновения коморбидной патологии и существенным отрицательным влиянием на качество жизни пациентов. По различным данным, псориазом страдает от 2 до 4% мирового населения, распространенность в педиатрической популяции составляет 1,4%, средний возраст манифестации заболеванияот 30 до 39 и от 50 до 69 лет [1]. Ранее псориаз классически характеризовался нарушением кератинизации, однако при изучении патогенетических механизмов, лежащих в основе заболевания, было выявлено, что скорее имеет место изменение механизмов взаимодействия между иммунными клетками и кератиноцитами [1].…”

“…По различным данным, псориазом страдает от 2 до 4% мирового населения, распространенность в педиатрической популяции составляет 1,4%, средний возраст манифестации заболеванияот 30 до 39 и от 50 до 69 лет [1]. Ранее псориаз классически характеризовался нарушением кератинизации, однако при изучении патогенетических механизмов, лежащих в основе заболевания, было выявлено, что скорее имеет место изменение механизмов взаимодействия между иммунными клетками и кератиноцитами [1]. По данным исследований, устранение системного воспаления приводит не только к клиническому улучшению дерматологических проявлений, но и к задержке появления сопутствующих воспалительных заболеваний [2].…”